Core 03: Tumor Imaging Metrics

核心 03：肿瘤成像指标

• 批准号: 10062885
• 负责人: GORDON J HARRIS
• 金额: $ 17.85万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-10 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10062885
• 关键词: 3-Dimensional; Cancer Center; Certification; Clinical Investigator; Clinical Trials; Clinical trial protocol document; Collection; Consultations; Dana-Farber Cancer Institute; Databases; Discipline of Nuclear Medicine; Enrollment; Faculty; General Hospitals; Guidelines; Home; Hospitals; Image; Institution; Knowledge; Lesion; Magnetic Resonance Imaging; Massachusetts; Measurement; Mission; Modality; Online Systems; Patient Care; Patients; Physicians; Positron-Emission Tomography; Protocols documentation; Radiology Specialty; Reporting; Research Personnel; Resource Sharing; Resources; Scanning; Secure; Services; Site; Specialist; Standardization; Time; Training; Training and Education; Woman; X-Ray Computed Tomography; cancer clinical trial; cancer imaging; clinical trial analysis; data access; imaging study; individual patient; medical schools; mid-career faculty; professor; radiologist; response; service member; statistics; treatment response; tumor; web site

Tumor Imaging Metrics Shared Resource Project Summary / Abstract The Tumor Imaging Metrics Core provides objective assessment of tumor response to treatment for patients enrolled in oncology clinical trials. All major radiological assessment criteria are supported including: RECIST (1.0 and 1.1), Cheson (2007 and 2009), IWCLL, RANO, PET SUV, PCWG2, Choi, 3D Volume, and irRC. For each patient, target and non-target lesions are selected according to the assessment criteria guidelines and are tracked longitudinally. Users are able to log into the website from anywhere at any time to access data and order a request for scan analysis. Quantitative analysis of CT, MR, and PET imaging studies are performed on a variety of modality-specific workstations. After scans are analyzed, the measurement results are reviewed and finalized by Harvard faculty radiologists and/or nuclear medicine physicians. Measurement results are stored in the Core database on a secure website and are viewable online by authorized trial staff. The quantitative measurements are used to determine tumor response to treatment and ultimately guide patient care. Summary statistics for the trial are presented as well as individual patient measurements. Rates for services are very reasonable compared to other options available from outside DF/HCC.

肿瘤成像指标共享资源 项目总结/摘要 肿瘤成像核心为患者提供肿瘤治疗反应的客观评估 参加了肿瘤临床试验。支持所有主要放射学评估标准，包括：RECIST (1.0和1.1）、Cheson（2007和2009）、IWCLL、RANO、PET SUV、PCWG 2、Choi、3D Volume和irRC。为 根据评估标准指南选择每个患者、靶病变和非靶病变， 纵向跟踪。用户可以随时随地登录网站访问数据， 请求扫描分析。对CT、MR和PET成像研究进行定量分析， 各种特定模式的工作站。扫描分析后，检查测量结果 并由哈佛学院放射科医师和/或核医学医师最终确定。测量结果 存储在安全网站上的核心数据库中，并可由授权的试验工作人员在线查看。的 定量测量用于确定肿瘤对治疗的反应并最终指导患者 在乎列出了试验的汇总统计量以及个体患者测量值。率 与DF/HCC外部提供的其他选项相比，这些服务非常合理。